肝细胞癌早期诊断血清学标志物的研究进展

朱明玉; 陈洁; 张欣欣

doi:10.3969/j.issn.1001-5256.2014.10.029

肝细胞癌早期诊断血清学标志物的研究进展

DOI: 10.3969/j.issn.1001-5256.2014.10.029

上海交通大学医学院附属瑞金医院感染科

基金项目:

国家国际科技合作项目(S2012GR0046)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2568
- HTML全文浏览量: 16
- PDF下载量: 712
- 被引次数: 0
出版历程
- 收稿日期: 2013-12-04
- 出版日期: 2014-10-20

Research advances in serum biomarkers for early diagnosis of hepatocellular carcinoma

Department of Infectious Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University

Research funding:

摘要

摘要: 肝细胞癌(HCC)是一种发生率和致死率均较高的严重威胁人类健康的疾病。目前尚无一种血清学指标可以单独早期诊断HCC。总结了近年发现对HCC早期诊断有潜在价值的血清学标志物,并对其在诊断HCC的敏感性和特异性以及判断疾病进展等方面进行阐述,认为对HCC早期诊断应通过联合其他血清学标志物以弥补甲胎蛋白在敏感性方面的不足。
- 癌,肝细胞 /
- 早期诊断 /
- 血清学标志物 /
- 综述
Abstract: Hepatocellular carcinoma ( HCC) is a disease with high incidence and mortality and has become a serious threat to human health.So far, none of the available markers can be used alone for early diagnosis of HCC. Recently identified serum markers with potential clinical value for early diagnosis of HCC are summarized, and their diagnostic sensitivity and specificity, as well as their applications in assessment of progression of the disease, are reviewed. It is suggested that alpha-fetoprotein should be used in combination with other serum markers to achieve accurate diagnosis of HCC at early stages.
- carcinoma, hepatocellular /
- early diagnosis /
- serum biological markers /
- reciew

HTML全文

参考文献(34)

[1]FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBO-CAN 2012[J].Int J Cancer, 2014.[Epub ahead of print]

[2]KUMADA T, NAKANO S, TAKEDA I, et al.Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma:special reference to imaging diagnosis[J].J Hepatol, 1999, 30 (1) :125-130.

[3]ODA K, IDO A, TAMAI T, et al.Highly sensitive lens culinaris agglutinin-reactive alpha-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease[J].Oncol Rep, 2011, 26 (5) :1227-1233.

[4]KUMADA T, TOYODA H, TADA T, et al.High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma[J].J Gastroenterol, 2014, 49 (3) :555-563.

[5]HSU HC, CHENG W, LAI PL.Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma:biological significance and temporospatial distribution[J].Cancer Res, 1997, 57 (22) :5179-5184.

[6]NAKATSURA T, YOSHITAKE Y, SENJU S, et al.Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker[J].Biochem Biophys Res Commun, 2003, 306 (1) :16-25.

[7]HIPPO Y, WATANABE K, WATANABE A, et al.Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma[J].Cancer Res, 2004, 64 (7) :2418-2423.

[8]DI TOMMASO L, FRANCHI G, PARK YN, et al.Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis[J].Hepatology, 2007, 45 (3) :725-734.

[9]LIBBRECHT L, SEVERI T, CASSIMAN D, et al.Glypican-3expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules[J].Am J Surg Pathol, 2006, 30 (11) :1405-1411.

[10]FILMUS J, CAPURRO M.Glypican-3:a marker and a therapeutic target in hepatocellular carcinoma[J].FEBS J, 2013, 280 (10) :2471-2476.

[11]LUO WM, CHEN L, CAO YL, et al.Diagnostic significance of combined application of serum GP73 and AFP-L3 in patients with PHC[J].J Clin Exp Med, 2013, 12 (13) :1005-1009. (in Chinese) 罗文明, 陈琳, 曹亚丽, 等.血清GP73及AFP-L3检测在原发性肝癌诊断中的意义[J].临床和实验医学杂志, 2013, 12 (13) :1005-1009.

[12]KLADNEY RD, CUI X, BULLA GA, et al.Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease[J].Hepatology, 2002, 35 (6) :1431-1440.

[13]HOU SC, XIAO MB, NI RZ, et al.Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma[J].Oncol Lett, 2013, 6 (4) :1152-1158.

[14]BA MC, LONG H, TANG YQ, et al.GP73 expression and its significance in the diagnosis of hepatocellular carcinoma:a review[J].Int J Clin Exp Pathol, 2012, 5 (9) :874-881.

[15]GU Y, CHEN W, ZHAO Y, et al.Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases[J].Ann Clin Biochem, 2009, 46 (Pt 1) :38-43.

[16]HU JS, WU DW, LIANG S, et al.GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population[J].Med Oncol, 2010, 27 (2) :339-345.

[17]XU YY, LIU YP.Correlation between midkine and malignant tumors[J].J Med Mol Biol, 2007, 4 (4) :347-349. (in Chinese) 徐莹莹, 刘云鹏.Midkine和恶性肿瘤[J].医学分子生物学杂志, 2007, 4 (4) :347-349.

[18]HUNG YJ, LIN ZH, CHENG TI, et al.Serum midkine as a prognostic biomarker for patients with hepatocellular carcinoma[J].Am J Clin Pathol, 2011, 136 (4) :594-603.

[19]CUI R, HE J, ZHANG F, et al.Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein[J].Br J Cancer, 2003, 88 (12) :1878-1882.

[20]INAGAKI Y, TANG W, XU H, et al.Des-gamma-carboxyprothrombin:clinical effectiveness and biochemical importance[J].Biosci Trends, 2008, 2 (2) :53-60.

[21]GAO JJ, INAGAKI Y, XUE X, et al.c-Met:a potential therapeutic target for hepatocellular carcinoma[J].Drug Discov Ther, 2011, 5 (1) :2-11.

[22]OH BK, KIM H, PARK YN, et al.High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis[J].Lab Invest, 2008, 88 (2) :144-152.

[23]MIURA N, OSAKI Y, NAGASHIMA M, et al.A novel biomarker TERTmRNA is applicable for early detection of hepatoma[J].BMC Gastroenterol, 2010, 10:46.

[24]LECHEL A, MANNS MP, RUDOLPH KL.Telomeres and telomerase:new targets for the treatment of liver cirrhosis and hepatocellular carcinoma[J].J Hepatol, 2004, 41 (3) :491-497.

[25]KONG SY, PARK JW, KIM JO, et al.Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma[J].J Cancer Res Clin Oncol, 2009, 135 (8) :1091-1098.

[26]FRIEDMAN RC, FARH KK, BURGE CB, et al.Most mammalian mRNAs are conserved targets of microRNAs[J].Genome Res, 2009, 19 (1) :92-105.

[27]LI L, GUO Z, WANG J, et al.Serum miR-18a:a potential marker for hepatitis B virus-related hepatocellular carcinoma screening[J].Dig Dis Sci, 2012, 57 (11) :2910-2916.

[28]YAMAMOTO Y, KOSAKA N, TANAKA M, et al.MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma[J].Biomarkers, 2009, 14 (7) :529-538.

[29]QI P, CHENG SQ, WANG H, et al.Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection[J].PLoS One, 2011, 6 (12) :e28486.

[30]SUN J, LU H, WANG X, et al.MicroRNAs in hepatocellular carcinoma:regulation, function, and clinical implications[J].The Scientific World J, 2013, 2013:924206.

[31]MA LX, WEI XH, ZHANG J.Recent perspectives on the role of microRNAs of the miR-15 family in liver disease[J].J Clin Hepatol, 2013, 29 (2) :158-160. (in Chinese) 马丽霞, 韦新焕, 张晶.miR-15家族在肝脏疾病中的作用[J].临床肝胆病杂志, 2013, 29 (2) :158-160.

[32]HE Y, MENG XM, HUANG C, et al.Long noncoding RNAs:Novel insights into hepatocelluar carcinoma[J].Cancer Lett, 2014, 344 (1) :20-27.

[33]XIE H, MA H, ZHOU D.Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma[J].Biomed Res Int, 2013, 2013:136106.

[34]LAI MC, YANG Z, ZHOU L, et al.Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation[J].Med Oncol, 2012, 29 (3) :1810-1816.

施引文献

资源附件(0)

访问统计